Imfinzi (Durvalumab) – NSCLC | DengYue Medicine

Imfinzi Application Scope

Imfinzi is a human monoclonal antibody that targets PD-L1 (programmed death-ligand 1), used as an immunotherapy for NSCLC.

Characteristics

• Ingredients: Durvalumab

• Properties:

  • Binds to PD-L1, blocking its interaction with PD-1 and CD80

  • Enhancing T-cell activation against tumors5

  • Does not induce antibody-dependent cellular cytotoxicity (ADCC)

• Packaging Specification: 120 mg/2.4 mL (50 mg/mL) and 500 mg/10 mL (50 mg/mL)

• Storage:

  • Store at 2°C–8°C (36°F–46°F) in original packaging; protect from light16.

  • Do not freeze or shake

• Expiry Date: ​Typically up to 24 months from manufacture if stored properly

• Executive Standard: Complies with FDA, EMA, and other regulatory standards

• Approval Number:

  • FDA BLA No.: 125069 (US)6.

  • EMA Product No.: EMEA/H/C/004771 (EU)

• Date of Revision:

  • Latest FDA label update: 2024 (for new dosing regimens)

• Manufacturer: AstraZeneca (produced by Vetter Pharma-Fertigung GmbH & Co KG, Germany)

Guidelines for the Use of Imfinzi

• Dosage and Administration: 10 mg/kg every 2 weeks or 1500 mg every 4 weeks (fixed dose)

• Adverse Reactions:

  • Common (≥10%): Fatigue, cough, nausea, musculoskeletal pain, constipation, decreased appetite

  • Serious:

    • Immune-mediated pneumonitis, hepatitis, colitis

    • Endocrine disorders (thyroid dysfunction, adrenal insufficiency)

• Contraindications: Hypersensitivity to durvalumab or its excipients

• Precautions:

  • Monitor for immune-related adverse reactions (pneumonitis, hepatitis, colitis)

  • Risk of infection; withhold for severe infections

Imfinzi Interactions

• Drug Interactions:

  • No formal studies

  • But avoid concurrent immunosuppressants unless necessary

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.